Role of the tPA/plasmin System in Alzheimers Disease

tPA/纤溶酶系统在阿尔茨海默病中的作用

基本信息

  • 批准号:
    7480226
  • 负责人:
  • 金额:
    $ 37.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-09-25 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall hypothesis of this proposal is that the tissue plasminogen activator/plasminogen (tPA/plg) fibrinolytic cascade, a proteolytic system which has been implicated in the clearance of amyloid-beta (A-beta) peptide, is an important pathway to investigate for developing possible therapeutic agents against Alzheimer's disease (AD). The abnormal deposition of A-beta in the parenchyma and blood vessels of the brain is a pathological hallmark of AD, the most common cause of dementia and cognitive decline in the aged. Additionally, epidemiological studies indicate that diseases that compromise the circulatory system are risk factors for the development of AD, and imply that AD has a cerebrovascular component. The objectives of this proposal are to investigate the role of the tPA/plg system in the progression of AD-like pathology in transgenic mice overexpressing the amyloid-beta precursor protein (A-betaPP). The tPA/plg system activity is depressed in AD transgenic mice and in individuals with AD, due to the expression of plasminogen activator inhibitor-1 (PAl-l), a protein overexpressed during inflammation, commonly seen in AD. To accomplish this goal, we propose three specific aims. First, we plan to investigate the effects of the loss of tPA, plg, or PAl-1 expression in A-betaPP transgenic mice in a C57/BI6 background. Second, we plan to investigate the role of fibrin deposition in exacerbating the pathology and cerebrovascular dysfunction in AD. Third, we plan to identify new compounds that block the interaction of PAl-1 and tPA, and to test these, along with known PAl-1 inhibitors, for their effects in AD mouse models. These experiments will take advantage of transgenic and knockout mouse lines as in vivo paradigms for the development of possible therapeutic intervention strategies, targeting the tPA/plasmin cascade, against AD progression
描述(由申请人提供):该提议的总体假设是组织纤溶酶原激活物/纤溶酶原(tPA/plg)纤溶级联,一种与淀粉样蛋白-β(A-β)肽清除有关的蛋白水解系统,是研究开发可能的阿尔茨海默病(AD)治疗剂的重要途径。A-β在脑实质和血管中的异常沉积是AD的病理标志,AD是老年人痴呆和认知能力下降的最常见原因。此外,流行病学研究表明,损害循环系统的疾病是AD发展的危险因素,并暗示AD具有脑血管成分。本研究的目的是研究tPA/plg系统在过表达淀粉样β前体蛋白(A-betaPP)的转基因小鼠中AD样病理学进展中的作用。由于纤溶酶原激活物抑制剂-1(PAI-1)的表达,tPA/plg系统活性在AD转基因小鼠和患有AD的个体中被抑制,PAI-1是一种在炎症期间过表达的蛋白质,在AD中常见。为了实现这一目标,我们提出了三个具体目标。首先,我们计划研究在C57/BI 6背景下A-β PP转基因小鼠中tPA、plg或PA 1 -1表达丧失的影响。其次,我们计划研究纤维蛋白沉积在加重AD病理和脑血管功能障碍中的作用。第三,我们计划鉴定阻断PAI-1和tPA相互作用的新化合物,并测试这些化合物,沿着已知的PAI-1抑制剂,在AD小鼠模型中的作用。这些实验将利用转基因和基因敲除小鼠品系作为体内范例,用于开发针对tPA/纤溶酶级联的可能的治疗干预策略,以对抗AD进展

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SIDNEY STRICKLAND其他文献

SIDNEY STRICKLAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SIDNEY STRICKLAND', 18)}}的其他基金

Mechanisms of Alcohol-Induced Tissue Injury
酒精引起的组织损伤的机制
  • 批准号:
    7758543
  • 财政年份:
    2005
  • 资助金额:
    $ 37.06万
  • 项目类别:
Mechanisms of Alcohol-Induced Tissue Injury
酒精引起的组织损伤的机制
  • 批准号:
    7389585
  • 财政年份:
    2005
  • 资助金额:
    $ 37.06万
  • 项目类别:
Mechanisms of Alcohol-Induced Tissue Injury
酒精引起的组织损伤的机制
  • 批准号:
    7214186
  • 财政年份:
    2005
  • 资助金额:
    $ 37.06万
  • 项目类别:
Mechanisms of Alcohol-Induced Tissue Injury
酒精引起的组织损伤的机制
  • 批准号:
    7056215
  • 财政年份:
    2005
  • 资助金额:
    $ 37.06万
  • 项目类别:
Mechanisms of Alcohol-Induced Tissue Injury
酒精引起的组织损伤的机制
  • 批准号:
    6919633
  • 财政年份:
    2005
  • 资助金额:
    $ 37.06万
  • 项目类别:
Mechanisms of Alcohol-Induced Tissue Injury
酒精引起的组织损伤的机制
  • 批准号:
    7589789
  • 财政年份:
    2005
  • 资助金额:
    $ 37.06万
  • 项目类别:
Genetics and Cell Biology
遗传学和细胞生物学
  • 批准号:
    7123154
  • 财政年份:
    2004
  • 资助金额:
    $ 37.06万
  • 项目类别:
Genetics and Cell Biology
遗传学和细胞生物学
  • 批准号:
    10216269
  • 财政年份:
    2004
  • 资助金额:
    $ 37.06万
  • 项目类别:
Role of the tPA/plasmin System in Alzheimers Disease
tPA/纤溶酶系统在阿尔茨海默病中的作用
  • 批准号:
    7112914
  • 财政年份:
    2004
  • 资助金额:
    $ 37.06万
  • 项目类别:
Role of Fibrinogen in Alzheimer's Disease
纤维蛋白原在阿尔茨海默病中的作用
  • 批准号:
    8277887
  • 财政年份:
    2004
  • 资助金额:
    $ 37.06万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 37.06万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 37.06万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 37.06万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 37.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 37.06万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 37.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了